Abstract: Methods are provided measuring L-lysine using a variant enzyme, an L-lysine measurement kit, and an enzyme sensor. Variant L-amino acid oxidase having a predetermined amino acid mutation, and having oxidase activity that is highly substrate-specific for L-lysine; a method for measuring L-lysine using this variant enzyme; an L-lysine measurement kit; and an enzyme sensor are also provided.
Abstract: The invention relates to a method of modifying a yeast cell for the production of ethanol. According to some embodiments of the invention, the activity of the Gpd1 protein and/or the Gpd2 protein is reduced.
Type:
Grant
Filed:
October 29, 2008
Date of Patent:
November 3, 2015
Assignee:
Danisco US Inc.
Inventors:
Elke Nevoigt, Stephane Guillouet, Carine Bideaux, Sandrine Alfenore, Georg Hubmann
Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.
Type:
Grant
Filed:
April 17, 2012
Date of Patent:
November 3, 2015
Assignee:
Genomatica, Inc.
Inventors:
Mark J. Burk, Anthony P. Burgard, Robin E. Osterhout, Jun Sun
Abstract: The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN? subtilase and to TY145 and BPN? variants having altered properties as compared to the parent TY145/BPN? subtilase.
Abstract: Methods of qualitatively and/or quantitatively detecting the presence of mutations, modifications or impurities in a protein sample are provided. The methods utilize isotopically labeled variants of amino acids incorporated into proteins prior to protein digest to enable comparisons of two protein samples in bottom-up liquid chromatography.
Abstract: The invention relates to a novel 3D structure encoding a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.
Type:
Grant
Filed:
May 23, 2014
Date of Patent:
September 15, 2015
Assignee:
Novozymes A/S
Inventors:
Leonardo De Maria, Carsten Andersen, Lars Lehmann Hyllling Christensen, Soren Flensted Lassen, Peter Rahbek Ostergaard
Abstract: The present invention relates to novel subtilase variants exhibiting improvements relative to the parent subtilase in one or more properties including: wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g., cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.
Type:
Grant
Filed:
January 15, 2010
Date of Patent:
September 15, 2015
Assignee:
NOVOZYMES A/S
Inventors:
Henriette Draborg, Vibeke Skovgaard Nielsen, Stefan Minning
Abstract: Provided is a novel method for preparing metabolites of atorvastatin using bacterial cytochrome P450, and a composition therefor, and more particularly, a composition for preparing 2-hydroxylated product of 4-hydroxylated product from atorvastatin including bacterial cytochrome P 450 BM3 (CYP102A1), CYP102A1 mutants, and chimeras derived from the CYP102A1 mutants, a kit therefor, and a method for preparing thereof.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
September 8, 2015
Assignee:
INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
Inventors:
Chul-Ho Yun, Dong-Hyun Kim, Ji-Yeon Kang, Sun-Ha Park, Sang-Hoon Ryu
Abstract: The present invention relates to a novel method of producing 3-hydroxypropionic acid from glycerol, and more particularly to a method of producing 3-hydroxypropionic acid by culturing in a glycerol-containing medium a mutant microorganism obtained by amplifying an aldehyde dehydrogenase-encoding gene in a microorganism having the abilities to produce coenzyme B12 and produce 3-hydroxypropionic acid using glycerol as a carbon source. The present invention enables the fermentation of glycerol even under microaerobic or aerobic conditions without having to add coenzyme B12. Thus, the invention will be very suitable for the development of biological processes for producing large amounts of 3-hydroxypropionic acid.
Type:
Grant
Filed:
October 29, 2009
Date of Patent:
July 28, 2015
Assignee:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors:
Chul-Ho Kim, Jeong-Woo Seo, Lianhua Luo, Baek Rock Oh, Pil-Soo Seo, Sun-Yeon Heo
Abstract: The invention relates to recombinant expression of variant forms of C1 CBH1a and homologs thereof, having improved thermostability, low-pH tolerance, specific activity and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.
Type:
Grant
Filed:
May 9, 2014
Date of Patent:
July 14, 2015
Assignee:
Codexis, Inc.
Inventors:
Vesna Mitchell, Grzegorz Wojciechowski, Oscar Alvizo
Abstract: Described herein are methods, compositions and synthetic biology approaches for solvent production, including but not limited to butanol production. Described herein are recombinant bacteria and yeast strains which may be used in production of a solvent, including but not limited to butanol, from lignocellulosic and other plant-based feedstocks. Described herein are methods of producing solvents, including but not limited to butanol, using bacteria and yeast strains. Described herein are methods of producing organisms that display highly efficient butanol production.
Type:
Grant
Filed:
May 19, 2008
Date of Patent:
July 14, 2015
Assignees:
The Board of Trustees of the University of Illinois, Eastman Renewable Materials, LLC
Inventors:
Hans P. Blaschek, Steven F. Stoddard, Zhen Shi
Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.
Type:
Grant
Filed:
January 27, 2012
Date of Patent:
July 7, 2015
Assignees:
Allergan, Inc., Syntaxin Limited
Inventors:
Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, K. Roger Aoki, Joseph Francis, Lance Steward
Abstract: In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites and is covalently linked to a cysteine residue of the lectins; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.
Type:
Grant
Filed:
July 22, 2011
Date of Patent:
June 30, 2015
Assignee:
SMART CELLS, INC.
Inventors:
Thomas M. Lancaster, Robert Butters, Naomi Choodnovskiy, Todd C. Zion
Abstract: A transglutaminase protein which is mutated to have improved heat resistance and/or pH stability. A mutation is introduced into WT transglutaminase at a cysteine residue capable of forming a disulfide bond (SS bond).
Abstract: A method of counting protein subunits to determine the oligomeric state of an oligomeric protein complex includes tagging and expressing the protein subunits with a mass/charge tag and selectively removing each mass/charge tag. The number of protein subunits of the oligomeric complex corresponds to the number of mass/charge tags removed.
Abstract: The invention provides variants of the Clostridium thermocellum endoglucanase (CelG) that have improved endoglucanase activity compared to the wild type enzyme. Also provided are related polynucleotides, compositions, vectors, host cells, and methods of use.
Type:
Grant
Filed:
March 10, 2010
Date of Patent:
April 14, 2015
Assignee:
Codexis, Inc.
Inventors:
Jie Yang, Xiyun Zhang, Ish Kumar Dhawan, Andrew Shaw
Abstract: The present invention relates to pectate lyase variants exhibiting alterations relative to a parent enzyme exhibiting pectate lyase activity as its major enzymatic activity; to a method of producing such enzymes; and to methods for using such enzymes in the textile, detergent and cellulose fiber processing industries. Compared to the parent enzyme, the pectate lyase variants of the present invention exhibit improved stability in detergents.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
April 14, 2015
Assignee:
Novozymes A/S
Inventors:
Sanne Schoeder Glad, Carsten Andersen, Torben Vedel Borchert, Katja Salomon Johansen, Henrik Frisner, Mads Eskelund Bjornvad, Thomas Thisted
Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.
Abstract: Fatty acid 13-hydroperoxide lyase proteins which have been modified with respect to a previously described guava 13-hydroperoxide lyase and the nucleic acid sequences encoding these proteins. Also, recombinant nucleic acid molecules for expressing the modified 13-hydroperoxide lyases and methods of using such lyases in the field of organic synthesis.